Company news
Verrica Pharmaceuticals Inc. news in 2025
Verrica Pharmaceuticals Inc.'s news releases, calls and decks from 2025, newest first.
Verrica Pharmaceuticals Announces Private Placement Financing of $50 Million to Retire Debt and Extend Cash Runway
November 24, 2025
Verrica Pharmaceuticals Reports Third Quarter 2025 Financial Results
November 14, 2025
Verrica Pharmaceuticals Presents New Data on VP-315 from its Phase 2 Clinical Trial in Basal Cell Carcinoma at the 40th Society for Immunotherapy of Cancer Annual Meeting
November 10, 2025
Verrica Pharmaceuticals Receives Positive Feedback from the European Medicines Agency (EMA) Supporting a Clear Regulatory Path Forward to File for Approval of YCANTH® in the European Union
October 20, 2025
Verrica Pharmaceuticals to Present New Data on VP-315 from its Phase 2 Trial in Basal Cell Carcinoma (BCC) at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting
October 7, 2025
Verrica Pharmaceuticals Announces That Development Partner, Torii Pharmaceutical, Receives Approval for YCANTH® (TO-208) in Japan for the Treatment of Molluscum Contagiosum
September 19, 2025
Verrica Pharmaceuticals to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
September 2, 2025
Verrica Pharmaceuticals Reports Second Quarter 2025 Financial Results
August 12, 2025
Verrica Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide a Corporate Update on August 12, 2025
August 6, 2025
Verrica Pharmaceuticals Reports Strong Growth in YCANTH® Dispensed Applicator Units in 2Q 2025
July 9, 2025
Verrica Pharmaceuticals Announces Amendment to Collaboration and License Agreement with Torii Pharmaceutical to Launch Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts
July 1, 2025
Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New York
May 28, 2025
Verrica Pharmaceuticals Reports Quarterly 2025 Financial Results
May 13, 2025
Verrica Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 13, 2025
May 7, 2025
Verrica Pharmaceuticals to Participate in the Citizens Life Sciences Conference in New York
April 30, 2025
Verrica Pharmaceuticals Reports Strong Demand-Led Growth in YCANTH® Dispensed Applicator Units in First Quarter 2025
April 7, 2025
Verrica Pharmaceuticals Appoints Gavin Corcoran, M.D. to its Board of Directors
April 2, 2025
Verrica Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference
March 31, 2025
Verrica Pharmaceuticals Appoints Noah L. Rosenberg, M.D., as Chief Medical Officer
March 26, 2025
Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results
March 11, 2025
Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results and Provide a Corporate Update on March 11, 2025
March 3, 2025
Verrica Pharmaceuticals to Participate in the TD Cowen 45th Annual Health Care Conference in Boston
February 25, 2025
Verrica Pharmaceuticals Announces Presentation of Three Posters Featuring Positive Preliminary Topline Results of VP-315 for the Treatment of Basal Cell Carcinoma at the 2025 Winter Clinical Dermatology Conference
January 20, 2025
Calls in 2025
- Verrica Pharmaceuticals (NASDAQ:VRCA) Q3 2025 Earnings Call
Nov 17, 2025
Transcript - Verrica Pharmaceuticals (NASDAQ:VRCA) Q2 2025 Earnings Call
Aug 12, 2025
Transcript - Verrica Pharmaceuticals (NASDAQ:VRCA) Q1 2025 Earnings Call
May 13, 2025
Transcript - Verrica Pharmaceuticals (NASDAQ:VRCA) Q4 2024 Earnings Call
Mar 11, 2025
Transcript